



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Highlights of Changes in Protocols, PPPOs and Patient Handouts** – Filtration of Paclitaxel-nab (ABRAXANE®) Preparations
- **Provincial Systemic Therapy Program** – BCCA Compassionate Access Program (CAP) Website Upgrade
- **Cancer Drug Manual** – Revised: Eribulin, Methotrexate, Nivolumab, Topotecan
- **Benefit Drug List** – Revised: Injectable Hydrocortisone added to HLHETCSPA & Non-Specified Protocols with Tumour Site Codes Followed by “NOS”
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: CNMODPCV; Revised: UCNBEV, CNMODPCV, GIGAVCCT, GIGAVCFT, GUMVAC, ULUAVAFAT, LYCHOPR, USMAVFIPI, USMAVIPI
- **Website Resources and Contact Information**

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PPPOs AND PATIENT HANDOUTS

FILTRATION OF PACLITAXEL-NAB (ABRAXANE®) PREPARATIONS

Effective March 2016, all paclitaxel-nab containing protocols and PPPOs will be updated with the new requirement to filter all paclitaxel-nab preparations during drug administration using a 15 micron filter. Smaller filters (e.g. 0.2 micron filter used for etoposide, paclitaxel, etc.) should NOT be used as they may result in blockage of the filter. This change will also be reflected in the Cancer Drug Manual.

This practice change results from reports of thin proteinaceous strands being occasionally observed during visual inspection of the final drug preparations. These strands are formed from an interaction between paclitaxel-nab and the silicone oil lubricant used in some syringes and IV bags. The use of a 15 micron filter removes these strands without affecting the physicochemical properties of the preparation. Filtration also eliminates the need for routine visual inspection of the final product, and the need to check for the presence of silicone oil in the medical device used for drug preparation.

PROVINCIAL SYSTEMIC THERAPY PROGRAM

BCCA COMPASSIONATE ACCESS PROGRAM (CAP) WEBSITE UPGRADE

Effective 18 January 2016, several minor changes have been made to the Compassionate Access Program (CAP) [online](#) system. These changes were made to improve the system’s performance and usability, and include the following:

PROVINCIAL SYSTEMIC THERAPY PROGRAM

1. The main page only displays a list of incomplete requests by the user.
2. Filter buttons have been added to the top of the page to allow users to selectively view “approved” vs. “denied” requests that were submitted in the past 365 days.
3. Requests highlighted in yellow are those submitted more than 48 hours ago.

All other system functions remained unchanged. For any questions regarding these changes, please contact the CAP office at cap_bcca@bccancer.bc.ca.

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Eribulin Monograph:

- *Solution Preparation and Compatibility* section – information related to non-standard dilutions added

Methotrexate Monograph:

- *Parenteral Administration* section – rate of IV administration clarified

Nivolumab Monograph:

- *Solution Preparation and Compatibility* section – lower limit of drug concentration for product stability updated

Topotecan Monograph:

- *Supply and Storage* section – current formulation updated

BENEFIT DRUG LIST

REVISED PROGRAMS

The following programs have been revised on the BCCA [Benefit Drug List](#) effective 1 February 2016:

Protocol Title	Protocol Code	Benefit Status
Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and cycloSPORINE	HLHETCSPA	Class II (Injectable Hydrocortisone Added)
Not Specified	Other Tumour Site Code Followed by 'NOS' (e.g. LYNOS)	Class I (Injectable Hydrocortisone Added)

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
CNMODPCV	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Modified PCV Chemotherapy Of Brain Tumours Using Procarbazine, Lomustine (CCNU) and vinCRiStine

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UCNBEV	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Line for prescription date added to page 2</i>	Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine
CNMODPCV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Treatment cycle clarified for recurrent oligodendrogliomas</i>	Modified PCV Chemotherapy Of Brain Tumours Using Procarbazine, Lomustine (CCNU) and vinCRiStine
GIGAVCCT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Line for prescription date added to page 2</i>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Capecitabine and Trastuzumab (HERCEPTIN)
GIGAVCFT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Line for prescription date added to page 2</i>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Infusional Fluorouracil and Trastuzumab (HERCEPTIN)
GUMVAC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Methotrexate and doxorubicin administration clarified</i>	Therapy for Transitional Cell Cancers of the Urothelium using Methotrexate, vinBLAStine, DOXORubicin and CISplatin
ULUAVAFAT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minocycline added as prophylaxis for rash, formatted for TALLman lettering</i>	First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with AFAtinib
LYCHOPR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Booking chemo on both days 1 and 2 for cycle #1 clarified in Return Appointment section</i>	Treatment of Lymphoma with DOXORubicin, Cyclophosphamide, vinCRiStine, predniSONEand riTUXimab
USMAVFIPI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Toxicities management updated, formatted for TALLman lettering</i>	First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
USMAVIPI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Toxicities management updated, formatted for TALLman lettering</i>	Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN BN CONc
 Rob Watt, BSc(Pharm)